Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	₩45,500.00	-4.61%	81,763
23/07/26	₩47,700.00	+12.37%	102,461
22/07/26	₩42,450.00	+1.31%	71,340
21/07/26	₩41,900.00	-0.24%	96,300
20/07/26	₩42,000.00	-7.49%	72,015

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 24/07/2026			5-day change	1st Jan Change
45,500.00 ^KRW	-4.61%		+0.22%	-62.08%

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI

Market Cap	988B 677M 594M 553M 507M 953M 65.17B 968M 6.56B 2.56B 32.04B 2.54B 2.49B 111B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	881B 603M 530M 493M 452M 850M 58.11B 863M 5.85B 2.29B 28.57B 2.27B 2.22B 98.77B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
04-13	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
01-15	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
01-04	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
12-18	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
11-03	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

12-19	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Share Price

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-4.61%
1 week	+0.22%
Current month	-23.14%
1 month	-19.33%
3 months	-44.78%
6 months	-61.28%
Current year	-62.08%

1 week	39,250	48,900
1 month	39,250	63,400
Current year	39,250	146,600
1 year	20,500	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	16/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	22/10/2023
Olaf Christensen CTO	Chief Tech/Sci/R&D Officer	-	30/09/2021

Director	Title	Age	Since
Jin-Woo Jo BRD	Director/Board Member	54	21/05/2024
Seung-Ju Lee BRD	Director/Board Member	52	16/08/2016
Geoff Meyerson BRD	Director/Board Member	-	26/03/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Seung-Ju Lee	Free	Founder	3,388,000	-
21/02/25	Un-Nam Park	Free	Director	60,000	-
21/02/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	-4.61%	+0.22%	+97.40%	-	702M
WUXI APPTEC CO., LTD.	-1.92%	-1.57%	+48.70%	+84.37%	55.92B
ARGENX SE	+0.93%	+7.22%	+64.67%	+63.56%	56.67B
BIONTECH SE	-2.97%	-2.35%	-22.03%	-16.54%	23.28B
INSMED INCORPORATED	-0.46%	-1.29%	+3.28%	+422.58%	23.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	-0.56%	+36.00%	-3.93%	20.54B
GENMAB A/S	-1.34%	-0.63%	+29.60%	-32.53%	17.78B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	-1.63%	+37.07%	+589.93%	15.9B
PHARMAESSENTIA CORPORATION	-1.30%	-9.92%	+160.67%	+284.37%	14.64B
EXELIXIS, INC.	-0.50%	-0.98%	+23.62%	+178.38%	13.99B
Average	-1.32%	+1.26%	+47.90%	+174.47%	24.27B
Weighted average by Cap.	-0.82%	+1.49%	+43.50%	+136.99%

	2024	2025
Net sales	20.91B 14.32M 12.57M 11.69M 10.73M 20.16M 1.38B 20.47M 139M 54.25M 678M 53.74M 52.58M 2.34B	23.56M 16.14K 14.17K 13.18K 12.09K 22.72K 1.55M 23.07K 157K 61.15K 764K 60.57K 59.27K 2.64M
Net income	-5.74B -3.93M -3.45M -3.21M -2.95M -5.54M -379M -5.62M -38.12M -14.89M -186M -14.76M -14.44M -643M	-41.97B -28.74M -25.24M -23.47M -21.54M -40.47M -2.77B -41.1M -279M -109M -1.36B -108M -106M -4.7B
Net Debt	-90.47B -61.95M -54.41M -50.6M -46.43M -87.24M -5.97B -88.59M -601M -235M -2.93B -233M -228M -10.14B	-107B -73.34M -64.42M -59.9M -54.97M -103M -7.06B -105M -711M -278M -3.47B -275M -269M -12.01B